Immunome

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It focuses on oncology and infectious disease areas. It utilizes the proprietary human memory B cell platform to enable the discovery of novel antibodies in both these therapeutic areas because of the interrogation of memory B cells from patients who have learned to fight off these diseases. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

EXTON, Pa.--(BUSINESS WIRE)--Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Second Quarter 2021 Financial Results

Immunome Reports Second Quarter 2021 Financial Results

IMNM stock is having a great day today. The company is preparing to move forward with expedited testing for its delta variant treatment.

IMNM Stock: The Covid Treatment News That Has Immunome Soaring Today

Immunome Inc (NASDAQ:IMNM) is surging Tuesday morning after the company reported the pre-clinical testing results of its antibody cocktail.  Immunome announced that its three-antibody cocktail, IMM-BCP-01, demonstrated neutralizing activity against the SARS-CoV-2 Delta variant.

Why Immunome's Stock Is Soaring Today

Immunome Inc (NASDAQ: IMNM) has announced that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against COVI-19 Delta variant in pre-clinical pseudovirus testing.  Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.

Immunome Stock Jumps As COVID-19 Antibody Shows Preclinical Neutralizing Activity Against Delta Variant

The stock price of Immunome Inc (NASDAQ: IMNM) increased by over 35% pre-market. This is why it happened.

IMNM Stock Increases Over 35% Pre-Market: Why It Happened

EXTON, Pa.--(BUSINESS WIRE)--Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference

EXTON, Pa.--(BUSINESS WIRE)--Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board

EXTON, Pa.--(BUSINESS WIRE)--Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors

Immunome Appoints Franklyn G. Prendergast, M.D.

EXTON, Pa.--(BUSINESS WIRE)--Immunome to Present at the Jefferies Virtual Healthcare Conference

Immunome to Present at the Jefferies Virtual Healthcare Conference

Immunome Inc (NASDAQ: IMNM) has secured additional funding of $4.3 million from the Department of Defense (DoD) for the development of an antibody cocktail (IMM-BCP-01) to combat SARS-CoV-2 and its variants. The additional capital comes less than a year after an initial DOD award of $13.3 million, bringing the total commitment to Immunome to $17.6 million.

Immunome Secures Additional $4.3M Funding From DoD To Develop COVID-19 Antibody Cocktail

The stock price of Immunome Inc (NASDAQ: IMNM) increased by over 7% pre-market. This is why it happened.

Immunome (IMNM) Stock: Over 7% Increase Pre-Market Explanation

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports First Quarter 2021 Financial Results

Immunome Reports First Quarter 2021 Financial Results

The stock price of Immunome Inc (NASDAQ: IMNM) increased by over 10% pre-market. This is why it happened.

IMNM Stock: Over 10% Increase Pre-Market Explanation

In addition to encouraging preclinical data from the COVID-19 antibody cocktail announced today, Immunome Inc (NASDAQ: IMNM) has entered into a private placement agreement of approximately $27 million with the sale of 1 million units at $27 per unit. The offer price is at a 9% discount to Friday's closing price of $29.55.

Immunome Raises $27M Via Private Equity Placement At 9%

Immunome Inc (NASDAQ: IMNM) has announced antibody selection for its IMM-BCP-01 antibody cocktail and shared preclinical data showing that IMM-BCP-01 is effective against the current SARS-CoV-2 and its variants. In Syrian hamsters infected with live SARS-CoV-2 virus, IMM-BCP-01 reduced lung viral load as a treatment and prophylaxis.

Immunome's Stock Jumps On Its Antibody Cocktail Neutralizing Multiple COVID-19 Variants In Animal Studies

EXTON, Pa.--(BUSINESS WIRE)--Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Heads Toward IND Filing

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces $27 Million Private Placement

Immunome Announces $27 Million Private Placement

EXTON, Pa.--(BUSINESS WIRE)--Immunome announces the appointment of Corleen Roche as Chief Financial Officer

Immunome Appoints Corleen Roche as Chief Financial Officer

EXTON, Pa.--(BUSINESS WIRE)--Immunome appoints Dennis Giesing, Ph.D. to the role of Chief Development Officer

Immunome Appoints Dr. Dennis Giesing as Chief Development Officer

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. “The fourth quarter of 2020 was a transformational period for Immunome thanks to our successful initial public offering on the NASDAQ exchange, which raised $

Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced that it advanced its first oncology program into IND-enabling studies and anticipates filing an IND in the second half of 2021. The IL-38 target was identified through the interrogation of a B cell sample from a head and neck cancer patient using the Immunome discovery engine. IL-38 ap

Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies

The stock price of Immunome Inc (NASDAQ: IMNM) increased by 51.67%. This is why it happened.

News for Immunome Stock (IMNM)